AzTrials
AzTrials

Advanced CancerPhase 1NCT05128539

A Study Explore JS001+JS002 in Patients With Advanced Cancer

A Phase 1 study testing JS001(Toripalimab)+JS002 in people with Advanced Cancer, run by Shanghai Junshi Bioscience Co., Ltd. at 1 site in China.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This open-label phase I clinical study with clinical development phase will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS002 combined with Toripalimab in advanced cancer patients, who has failed standard therapy OR could not tolerate standard therapy OR refused/had no standard… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Advanced Cancer
What is being tested?
JS001(Toripalimab)+JS002
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteChina
Study dates
10 Feb 2022to 10 Nov 2023
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Fully understand and be willing to provide written informed consent;
  • Male or female with age ≥ 18 years and ≤75 years (At part B age ≥18 years);
  • The expected survival is ≥ 3 months;
  • ECOG PS 0 or 1;
  • Advanced tumor patients who have failed standard treatment (including PD-1/PD-L1), cannot tolerate standard treatment, OR refused/have no standard treatment (note: Patients with hepatocellular carcinoma, lung cancer and urothelial carcinoma that have failed PD-1 or PD-L1 treatment are preferred, and other types of the advanced tumor patients without standard treatment can be enrolled according to initial efficacy);
  • Having at least one measurable disease per RECIST 1.1.
Show all 13Show fewer
  • Agree to provide tumor tissue samples (fresh biopsy samples before treatment should be provided as far as possible; for patients who cannot provide fresh biopsy samples before treatment, archived samples can be provided within 2 years; for some patients who cannot provide qualified tumor tissue samples, they can also be included in the group after discussion and agreement between the investigator and the sponsor);
  • The results of laboratory tests during the screening period indicate that the patient has good organ function:
  • Hematology (no blood transfusion within 14 days and no treatment with blood components or granulocyte colony cytokines): i. Absolute neutrophil count ANC ≥ 1.5×109/L(1,500/mm3) ii. Platelets ≥ 100×109/L(Part B: ≥ 75×109/L) (100,000/mm3) iii. Hemoglobin ≥ 10.0g/dL (Part B: ≥ 9.0g/dL) b) Hepatic function: i. Serum total bilirubin(TBil) ≤1.5×ULN ; For patients with primary liver cancer, liver metastasis, or proven/suspected Gilbert's disease, TBil ≤ 2×ULN ii. AST and ALT ≤2.5 × ULN; ≤5×ULN in those with hepatic metastasis or primary liver cancer.
  • Renal function: i. Creatinine clearance(CrCl) ≥50mL/min(Cockcroft-Gault formula); ii. Urine protein ≤ 2+ (if the urine protein is 2+, the 24-h urine protein test will be performed, and only patients with ≤2g are eligible).
  • Coagulation function: International standardized ratio (PT/INR) and activated partial thrombin time (APTT) ≤1.5×ULN (for those receiving anticoagulant therapy, such as low molecular weight heparin or warfarin, the anticoagulant dose is required to be stable for at least 4 weeks without dose adjustment, and the coagulation parameters INR and APTT at screening are within the expected range of anticoagulant therapy) e) Endocrine function: Thyroid stimulating hormone (TSH) normal, or abnormal TSH but normal FT3 and/or FT4 (for patients with hypothyroidism with abnormal TSH but normal FT4) f) Cardiac function: QTc interval ≤ 460 ms for male and ≤ 480 ms for female, which is calculated according to Fridericia formula.
  • Men or women patients of childbearing potentials agree to use an effective method of contraception (e.g., oral contraceptives, intrauterine devices, or barrier contraception combined with spermicide) and continued to use contraception for 6 months after treatment.
  • Good compliance and follow-up.

Who cannot join

  • A history of malignancies other than the tumors described in this study within 5 years, with the exception of early malignancies that have been completely cured (no recurrence within 5 years), including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, and ductal carcinoma in situ after the radical mastectomy);
  • The patients received systemic antitumor drugs(chemotherapy, small molecular targeted drug therapy, hormone therapy, immunotherapy or biological treatment, etc.), local anti-tumor therapy (e.g., patients accepted palliative radiotherapy for bone metastases are eligible, in which the radiotherapy is performed more than 2 weeks before the baseline tumor assessment ), or clinical research drug/treatment instrument within 4 weeks prior to first dose;
  • Patients who have previously received PCKS9 inhibitor therapy;
  • Adverse reactions caused by previous treatment have not recovered to GRADE 1 or below per CTCAE (version 5.0) (except alopecia and neurotoxicity, which investigator judged could not be recovered for a long time);
  • Previous allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
  • Having untreated central nervous system metastasis, or meningeal metastasis. Patients who has received treatment for brain metastases are eligible if meet all the following criterion; stable condition is observed at least 3 months; no radiological progression is identified within 4 weeks prior to first dose; all the nervous system symptoms have returned to baseline levels; no new evidence or expanded brain metastases; has stopped radiotherapy, surgery or steroid therapy at least 28 days prior to first dose;
Show all 25Show fewer
  • Autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc., diagnosed within 2 years are ineligible, except for type I diabetes controlled by replacement therapy, skin diseases that do not require systemic treatment (e.g., psoriasis and vitiligo), endocrine diseases controlled by hormone replacement therapy (e.g., hypothyroidism);
  • Patients with associated clinical symptoms (dyspnea, wheezing, abdominal distension, etc.), uncontrolled or repetitive drainage of pleural/abdominal effusion or pericardial effusion. The patients with pleural/abdominal effusion are not allowed to accept intrapleural/intraperitoneal injection of anti-tumor agents accordingly;
  • Have serious cardiovascular and cerebrovascular diseases, such as poorly controlled hypertension (systolic blood pressure > 150mmHg and/or diastolic blood pressure > 100mmHg) or pulmonary hypertension as judged by the investigator; Unstable angina or myocardial infarction, coronary artery bypass grafting or stenting within 6 months prior to study use; Chronic heart failure with heart function grade 2 or greater (NYHA); Degree ⅱ or higher heart block; Grade ≥2 supraventricular or ventricular arrhythmias; Left ventricular ejection fraction (LVEF) < 50%; Cerebrovascular accident (CVA) or transient ischemic attack (TIA) occurred within 6 months prior to medication;
  • History of pulmonary disease: drug-induced interstitial lung disease or pneumonia, obstructive pulmonary disease that severely affects lung function, and symptomatic bronchospasm;
  • Has an active infection requiring systemic treatment;
  • Human immunodeficiency virus (HIV) antibody test positive;
  • Patients with non-alcoholic steatohepatitis, alcoholic/drug-related/autoimmune hepatitis or uncontrolled active hepatitis B virus (HBV), or hepatitis C virus (HCV):
  • Active HBV infection is defined as patients with surface antigen (HBsAg) positive and detectable DNA higher than the upper limit of the reference in each research center, accompanied with increased ALT; active HCV infection is defined as patients with positive HCV antibody and positive HCV RNA.
  • Patients with active HBV can take antiviral drugs, such as nucleoside (acid) analogues (NAs), as recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 edition). Prior to the first dose, patients with HBV DNA < 2000 IU/ mL can participate in this study.
  • Patients who test positive for HCV antibodies can only be enrolled in this study if the polymerase chain reaction (PCR) test is negative for HCV RNA. D) If the patients were receiving antiviral therapy at the time of enrollment and were required to maintain stable antiviral therapy throughout the study, any patients with compliance concerns were excluded from enrollment.
  • Active tuberculosis (TB) is known to exist. Patients suspected of having active TB should be examined for chest X-rays, sputum cytology, and clinical signs and symptoms.
  • Received systemic corticosteroids (prednisone > 10mg/ day or equivalent) or other immunosuppressive drugs within 14 days prior to the first dose;
  • Have received broad-spectrum antibiotics that may affect gut microbiota within 14 days prior to the first administration;
  • Receiving live or attenuated live vaccine within 4 weeks prior to the first administration;
  • Major surgical procedures (as defined by the investigator, e.g., open biopsy and severe trauma) were performed within 4 weeks prior to the first dose. Note: Intravenous drip replacement is acceptable. Patients who plan to accept major surgery within 30 days after the first dose or not yet fully recovered from previous surgery. Patients with local surgery (e.g., core needle biopsy and prostate biopsy) performed at least 24 h before the first administration are eligible;
  • Those who have a history of psychotropic drug abuse and cannot get rid of it or have a history of mental disorders;
  • Pregnant or lactating women;
  • Patients are allergic to JS002 or Toripalimab and their active ingredients or excipient;
  • Other severe, acute or chronic medical or psychiatric conditions or laboratory abnormalities that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with the interpretation of study results.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Henan Tumor Hospital

    Zhengzhou, Henan, 450003

Other trials in China

About this study

Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Humanized Anti-PCSK9 Monoclonal Antibody (JS002) Combined With Toripalimab in Patients With Advanced Cancer

This open-label phase I clinical study with clinical development phase will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS002 combined with Toripalimab in advanced cancer patients, who has failed standard therapy OR could not tolerate standard therapy OR refused/had no standard therapy.

This study is divided into two parts:

Part A. JS002 combined with Toripalimab dose escalation and dose expansion phase; Part B.JS002 combined with Toripalimab clinical expansion phase.

Conditions
Advanced Cancer
Being tested
JS001(Toripalimab)+JS002

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • JS001(Toripalimab)+JS002Drug

    Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.

    Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1.

Study groups in NCT05128539
Study groupRoleWhat they receive
JS001(Toripalimab)+JS002ExperimentalNot described
Receives: Drug: JS001(Toripalimab)+JS002

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. adverse events (AE)、SAE、irAE

    Safety endpoints: adverse events (AE), serious adverse events (SAE), and immune-related adverse events (irAE);

    Measured: 3 years

  2. Dose-limiting toxicities (DLTs)

    Safety endpoints

    Measured: 3 years

  3. MTD

    Maximum tolerated dose (MTD)

    Measured: 1 year

  4. Recommended dose for extension (RDE)

    Recommended dose for extension (RDE)

    Measured: 1 year

Secondary outcomes (15)

  1. ORR

    Efficacy endpoints: Objective response rate (ORR) based on RECIST 1.1 criteria

    Measured: 2 years

  2. DOR

    Efficacy endpoints: Uration of response (DOR) based on RECIST 1.1 criteria

    Measured: 2 years

  3. DCR

    Efficacy endpoints: Disease control rate (DCR) based on RECIST 1.1 criteria

    Measured: 2 years

  4. TTR

    Efficacy endpoints:Time to response (TTR) based on RECIST 1.1 criteria

    Measured: 2 years

  5. PFS

    Efficacy endpoints:progression-free survival (PFS) based on RECIST 1.1 criteria

    Measured: 2 years

  6. OS

    Efficacy endpoints:overall survival (OS) based on RECIST 1.1 criteria

    Measured: 2 years

  7. 1-year OS rate

    Efficacy endpoints: 1-year OS rate based on RECIST 1.1 criteria

    Measured: 1 year

  8. Pharmacokinetic (PK) characteristics

    Drug concentration of individual subjects at different time points after administration;

    Measured: 2 years

  9. Peak concentration（Cmax）

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) :peak concentration (Cmax) ;

    Measured: 2 years

  10. Peak time（Tmax）

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) ：peak time (Tmax) ;

    Measured: 2 year

  11. Area under blood concentration-time curve (AUC0-T and AUC0-)

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) :area under blood concentration-time curve (AUC0-T and AUC0-) ;

    Measured: 2 years

  12. Clearance rate (CL)

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) ：clearance rate (CL) ;

    Measured: 2 years

  13. Volume of distribution (Vss)

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) ：volume of distribution (Vss)

    Measured: 2 years

  14. Elimination half-life (T1/2)

    The pharmacokinetic parameters of JS002 and Toripalimab (JS001) ：elimination half-life (T1/2)

    Measured: 2 years

  15. ADA against

    Incidences of ADA against JS002 and Toripalimab (JS001), respectively

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2021
  2. Study start10 Feb 2022
  3. Primary completion10 Nov 2023
  4. Study completion10 Nov 2023

Why it stopped: The regimen of JS002 75\~300mg Q3W has been completed, and the combination therapy is well tolerated and safe. However, considering that the efficacy did not reach the preset, it is recommended to terminate the trial in advance.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05128539
Sponsor's protocol ID
JS001-046-I
Status last verified
Oct 2021
First submitted
27 Oct 2021
Last updated
26 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing JS001(Toripalimab)+JS002 in people with Advanced Cancer, run by Shanghai Junshi Bioscience Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 26 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: The regimen of JS002 75\~300mg Q3W has been completed, and the combination therapy is well tolerated and safe. However, considering that the efficacy did not reach the preset, it is recommended to terminate the trial in advance.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

adverse events (AE)、SAE、irAE (time frame: 3 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05128539.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in